1343 related articles for article (PubMed ID: 23727264)
1. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
4. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
5. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
6. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
[TBL] [Abstract][Full Text] [Related]
7. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Adorini L; Pruzanski M; Shapiro D
Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
[TBL] [Abstract][Full Text] [Related]
9. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the development of farnesoid X receptor agonists.
Ali AH; Carey EJ; Lindor KD
Ann Transl Med; 2015 Jan; 3(1):5. PubMed ID: 25705637
[TBL] [Abstract][Full Text] [Related]
12. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
[TBL] [Abstract][Full Text] [Related]
13. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Zhao J; Li B; Zhang K; Zhu Z
Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
[TBL] [Abstract][Full Text] [Related]
15. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
18. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Venetsanaki V; Karabouta Z; Polyzos SA
Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]